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AbstrACt
Objective New rapid and low-cost molecular tests for 
cervical cancer screening, such as the OncoE6 Cervical 
Test, are emerging and could be alternatives for low-
income and middle-income countries. To this end, we 
evaluated the clinical performance of the OncoE6 Cervical 
Test in detecting cervical intraepithelial neoplasia (CIN) 
among HIV-infected women in Bujumbura, Burundi.
Methods From June to December 2017, a cross-
sectional study was conducted in 680 HIV-positive 
women at the University Hospital. Women aged 25–65 
years who declared having had vaginal intercourse were 
consecutively recruited, and cervical specimens for 
OncoE6, liquid-based cytology and human papillomavirus 
(HPV) genotyping were obtained and visual inspection with 
acetic acid performed. Thereafter, participants underwent 
a colposcopic examination. The sensitivity, specificity, and 
positive and negative predictive values of the different 
tests were calculated with reference to ‘colposcopic-
histological’ diagnoses, and areas under the receiver 
operating curves of OncoE6 and cytology tests were 
compared.
results The prevalence of CIN was 4.9%, and OncoE6 
positivity was 3.1%. OncoE6 sensitivity varied from 
poor to low with increasing disease severity (42.1%, 
95% CI 19.9% to 64.3% at CIN2+ threshold; and 58.3%, 
95% CI 30.4% to 86.2% at CIN3+ threshold). OncoE6 
had the highest specificity compared with all other tests 
used together. The performance of the OncoE6 test was 
significantly lower compared with cytology at atypical 
squamous cell of undetermined significance (ASCUS+) 
cut-off (AUC=0.68 vs 0.85, p=0.03) and low-grade 
squamous intraepithelial lesion (LSIL+) cut-off (AUC=0.68 
vs 0.83, p=0.04) for CIN2+ diagnoses. However, the 
performance of the OncoE6 test was similar to that of 
cytology at high-grade squamous intraepithelial lesion 
(HSIL+) cut-off (AUC=0.68 vs 0.76; p=0.30) for CIN2+ 
diagnoses and was also similar to that of cytology at all 
cut-offs (ASCUS+, LSIL+ and HSIL+) for CIN3+ diagnoses 
(p1=0.76, p2=0.95 and p3=0.50, respectively).
Conclusion The current OncoE6 test proved to be a 
point-of-care test. However, given its poor performance 
for CIN2+ diagnoses, we do not recommend it for 
primary screening. We recommend to enrich it with more 
oncogenic HPV types, which may improve the performance 
of the test akin to that of cytology.
bACkgrOund
The causal relationship between infec-
tion with high-risk human papillomavirus 
(HR-HPV) and invasive cervical cancer (ICC) 
development is well established. Among the 
HR-HPV types, the 16 and 18 types cause 
more than 70% of all ICCs.1 Worldwide, ICC 
represents the fourth most common cancer 
among women, accounting for an estimated 
incidence and mortality rates of 13.1 and 6.9 
per 100 000 women, respectively.2 In low-in-
come and middle-income countries (LMICs), 
ICC is the second most common cancer 
among women, and this part of the world 
bears 87% of the ICC global burden.2 In 
Burundi, cervical cancer is the most common 
cancer in women (age-standardised inci-
dence and mortality rates of 57.4 and 50.3 
per 100 000 women, respectively), with a high 
mortality to incidence ratio related to a very 
strengths and limitations of this study
 ► This study is among the few studies evaluating the 
clinical performance of the OncoE6 Cervical Test 
in HIV-positive women, with a sufficiently powered 
sample size.
 ► Comprehensive efforts have been made to improve 
the precision of the parameter estimates by the use 
of a ‘composite colposcopic-histological diagnosis’, 
which is a reliable gold standard proxy.
 ► Women with normal-appearing cervix were not bi-
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low survival due to most women being diagnosed at a late 
stage.3
This high burden associated with HPV infection is 
more important in HIV-positive women since they bear 
an increased risk of HPV persistent infection,4 a high 
frequency of precancerous lesions and a rapid progres-
sion from precancerous lesions to invasive cancer, 
compared with their HIV-negative counterparts.5 As a 
corollary, HIV-infected women should be prioritised for 
cervical cancer control interventions.6–8
Currently available cervical cancer screening strate-
gies are HPV-based, cytology-based and visual inspec-
tion-based (acetic acid (VIA) and/or Lugol’s iodine 
(VILI)). Research has shown that HPV-DNA-based 
screening techniques are more effective tools for cervical 
cancer screening than the other two alternative tech-
niques.9–12 Current WHO recommendations for cervical 
cancer screening are HPV-based screening techniques 
where resources are available, whereas in low-resource 
settings WHO recommends VIA alone.8 13 HPV-based and 
cytology-based screening techniques are hardly imple-
mentable in LMICs due to their high cost, infrastructure 
requirements and need for well-trained staff, all condi-
tions that many LMICs, like Burundi, cannot satisfy.
The VIA screening modality is relatively less demanding 
since trained nurses can perform it with simple tools. 
However, this strategy has also several bottlenecks, 
including frequent training and supervision, along with 
its subjective interpretation, resulting in varying accuracy 
in different settings. Furthermore, there is evidence that 
increased inflammation among HIV-positive population 
affects the sensitivity and specificity of VIA.14 Despite its 
feasibility, these limitations are also hard to overcome in 
LMICs, which may explain the current delay or lack of 
adoption by policymakers in Burundi.
Given that HPV-based screening tests are resource-pro-
hibitive for LMICs, there are currently a number of rapid 
and cheaper molecular tests that could be used in LMICs, 
such as the OncoE6 Cervical Test. This molecular test does 
not require elaborate laboratory infrastructure or highly 
trained staff and is reproducible, thus making HPV-based 
screening test accessible even in resource-poor settings.
The OncoE6 Cervical Test is designed to detect 
elevated levels of E6 oncoproteins, which are disease-spe-
cific biomarkers required for epithelial cell transforma-
tion to occur.15 16 Previous findings of the OncoE6 test in 
the general population revealed its high specificity and 
positive predictive value.7 17–19 It was then hypothesised 
that the test could be useful to screen high-risk popu-
lations, including HIV-positive women. Nevertheless, 
notwithstanding its accuracy, this hypothesis has never 
been investigated, and large-scale evaluation among 
the highest risk groups, especially among HIV-infected 
women, is currently lacking. In view of the lack of access 
to cervical cancer screening that HIV-infected Burundian 
women face, the OncoE6 test may offer opportunities. 
To this end, we evaluated the clinical performance of the 
OncoE6 Cervical Test in detecting cervical intraepithelial 
neoplasia (CIN) among HIV-infected women in Bujum-
bura, Burundi.
MethOds
study design and population
A cross-sectional study was conducted in an HIV-clinic 
located in the University Hospital, Roi Khaled, in Bujum-
bura, from June to December 2017. Participants were 
HIV-positive women of age between 25 and 65 years, 
able to provide informed consent and declared having 
had vaginal intercourse during their lives. Women were 
excluded if they were pregnant, less than 6 weeks post 
partum, had a history of hysterectomy or treatment for 
cervical cancer.
enrolment visits and study-related procedures
Participants were given an education session about 
cervical cancer before the start of the study. A baseline 
questionnaire was administered to each participant to 
assess risk factors for cervical dysplasia and HPV infec-
tion. All women coming to the clinic for any reason were 
given an opportunity to participate in the study. Women 
were consecutively enrolled until the target sample size 
was reached. All participants underwent a physical exam-
ination of the pelvis. Women who reported or presented 
with abnormal vaginal discharge and lower pelvic pain 
were given syndromic sexually transmitted infection 
(STI) treatments following the WHO guidelines.13 These 
women on STI presumptive treatment were asked to 
return 2 weeks after treatment for screening and colpos-
copy. Women with menses were also asked to come back 
2 weeks later. The initial examination was performed by 
three nurses and a senior medical student in the last phase 
of residency who followed a 7-day training on VIA/VILI 
screening using the International Agency for Research on 
Cancer (IARC) training module.20 In addition, they were 
trained on specimen collection for the OncoE6 Cervical 
Test and liquid-based cytology (LBC).
The examination started by evaluating, in naked eye, 
the cervix to identify its landmarks. During this clinical 
examination, cervical specimens were collected in the 
following order: OncoE6 in dry tubes, LBC in ThinPrep 
vials (for both cytology and HPV-DNA testing), followed 
by VIA. One minute after the application of 5% acetic 
acid, the squamocolumnar junction (SCJ) was re-evalu-
ated using a lamp as source of light. We considered that 
a woman had a positive VIA result in case of a definite 
acetowhite lesion touching or abutting the SCJ, or if the 
entire cervix or a growth on the cervix turned acetowhite, 
as per the IARC guidelines.20
After sample collection, each participant underwent 
a standardised non-invasive colposcopy examination by 
two trained medical doctors. Colposcopic diagnoses were 
recorded using the modified Reid Colposcopic Index.21 
Colposcopic evaluation included naked eye inspection, 
and reapplication of acetic acid, green filter and Lugol’s 
iodine. An endocervical speculum was used to assist in 
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Figure 1 Flow diagram of participants. CIN, cervical 
intraepithelial neoplasia; HPV, human papillomavirus; ICC, 
invasive cervical cancer; LBC, liquid-based cytology.
visualising the endocervical canal if the entire SCJ was not 
seen. If, despite the use of endocervical speculum, the 
SCJ was not entirely seen, the colposcopy was considered 
unsatisfactory.
Cervical punch biopsies for histology confirmation 
were performed as clinically indicated on consenting 
participants with evidence of colposcopic cervical abnor-
malities, as dictated by the ethics committee. Results were 
reported as per the Richart CIN staging system,22 in five 
categories of increasing disease severity: normal, CIN1, 
CIN2, CIN3 and ICC. Biopsy specimens were stored in 
10% buffered formalin at room temperature until anal-
ysis. Cytology and histology reading, as well as Riatol 
quantitative PCR (qPCR) HPV genotyping (a clinically 
validated, laboratory-developed test which amplifies 18 
HPV types: HPV 6E6, 11E6, 16E7, 18E7, 31E6, 33E6, 
35E6, 39E7, 45E7, 51E7, 52E7, 53E6, 56E7, 58E7, 59E7, 
66E6, 67L1 and 68E7),23 were carried out at the Labo-
ratory of Molecular Pathology, AML, Antwerp, Belgium, 
by a cytologist and a pathologist blinded to colposcopic 
findings, and OncoE6 and VIA results. Cytology results 
were reported according to the Bethesda 2014 guidelines. 
The OncoE6 test was run at the recruitment site by one 
trained investigator (ZN, a medical doctor).
Considerations about sample size determination
In order to have 80% power to prove that the sensitivity 
of the OncoE6 Cervical Test was not inferior to that of a 
cytology screening test at a significance level of 0.05, we 
needed to include at least 674 HIV-positive women. We 
assumed that the sensitivity of the LBC was 0.80 at atypical 
squamous cell of undetermined significance (ASCUS) 
cut-off and 0.55 for the OncoE6 Cervical Test. A non-infe-
riority margin of 0.05 was taken into account.
statistical analysis
The five-level categories of Richart’s classification was 
collapsed into a four-level ordinal outcome variable as 
follows: no CIN, CIN1, CIN2 and CIN3+. Summary statis-
tics were generated for basic sociodemographic and clin-
ical information. Clinical performance of OncoE6, VIA 
and LBC (at ASCUS+, low-grade squamous intraepithelial 
lesion (LSIL+) and high-grade squamous intraepithelial 
lesion (HSIL+) thresholds) in predicting CIN2+ or CIN3+ 
diagnoses was evaluated using sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value 
(NPV), with their respective 95% CI. Values of sensitivity, 
specificity, PPV and NPV between 0% and ≤40% were 
considered as poor, between >40% and ≤60% as low, 
between >60% and ≤80% as moderate, and >80% as high.
Furthermore, the performance of the OncoE6 test was 
compared with the performance of LBC at ASCUS+, LSIL+ 
and HSIL+ cut-offs, respectively, by exploring the differ-
ences in areas under their respective receiver operating 
curves. To this end, we used the Stata command ‘roccomp 
status mod1 mod2, graph summary’, with status being the gold 
standard, mod1 being test 1 and mod2 being test 2. The 
differences in areas under the curves were considered statis-
tically significant at a p value <0.05. Our gold standard was 
based on (1) histopathological results for women in whom 
invasive procedures (punch biopsies) were performed and 
(2) diagnostic colposcopy results in women who had no 
clinical indication for undergoing invasive procedures.
Secondary analyses were performed to determine the 
performance of an algorithm composed of the Riatol HPV 
test followed by the OncoE6 Cervical Test, for women 
who tested positive with the Riatol HPV test, in detecting 
cervical lesions among HIV-positive women. Women with 
inconclusive colposcopic assessments (ie, unsatisfactory 
colposcopy), women who were eligible for histological 
confirmation but did not undergo biopsy procedures 
and one woman with invalid histopathology result were 
excluded from the analysis. All the analyses were carried 
out using the Stata V.15 software.
Patient and public involvement
Patients were not involved in the conception phase of the 
study. However, they were involved during the recruit-
ment phase by explaining to other women how they 
experienced the sample collection processes, and this 
contributed to reassurance among other participants. 
Each participant received the results of the screening 
tests and colposcopy findings and was advised on the 
screening periodicity. The authors will disseminate the 
findings via conference presentations and by submitting 
the manuscript to journals for publication.
results
Figure 1 presents the flow chart of study participants.
sociodemographic characteristics of study participants
Table 1 presents the sociodemographic characteris-
tics along with screening and colposcopic results of 
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Table 1 Distribution of sociodemographic characteristics as per the final disease outcome (final composite colposcopic-












Overall 680 (100) 647 (95.1) 14 (2.1) 7 (1.0) 12 (1.8)
Age
  Median (Q1, Q3) 44 (37, 52) 44 (38, 52) 37.5 (32, 42) 41 (40, 49) 43 (37.5, 51.5)
Education
  No education 114 (16.8) 101 (16.5) 3 (21.4) 0 (0.0) 4 (33.3)
  Went to primary school 361 (53.1) 346 (53.5) 7 (50.0) 3 (42.9) 5 (41.7)
  Went to high school 195 (28.7) 184 (28.4) 4 (28.6) 4 (57.1) 3 (25.0)
  Went to higher school 10 (1.5) 10 (1.6) 0 (0.0) 0 (0.0) 0 (0.0)
Marital status
  Married/cohabiting 286 (42.1) 271 (41.9) 7 (50.0) 5 (71.4) 3 (25.0)
  Single 25 (3.7) 23 (3.6) 1 (7.1) 0 (0.0) 1 (8.3)
  Divorced 122 (17.9) 115 (17.8) 3 (21.4) 1 (14.3) 3 (25.0)
  Widowed 247 (36.3) 238 (36.8) 3 (21.4) 1 (14.3) 5 (41.7)
Tobacco use
  Yes 27 (4.0) 26 (4.0) 0 (0.0) 0 (0.0) 1 (8.3)
Age at first sexual intercourse (n=679)
  Median (Q1, Q3) 18 (16, 20) 18 (16, 20) 17.5 (15, 20) 18 (16, 20) 18 (15, 20)
Lifetime sexual partners (n=679)
  1 140 (20.6) 136 (21.1) 3 (21.4) 1 (14.3) 0 (O.0)
  2+ 539 (79.4) 510 (78.9) 11 (78.6) 6 (85.7) 12 (100.0)
  Median (Q1, Q3) 3 (2, 4) 3 (2, 4) 3.5 (2, 4) 3 (2, 5) 4 (2, 5)
Sexual partners in the previous 6 months (n=679)
  0 291 (42.9) 278 (43.0) 5 (35.7) 1 (14.3) 7 (58.3)
  1 351 (51.7) 333 (51.6) 8 (57.1) 6 (85.7) 4 (33.3)
  2+ 37 (5.4) 35 (5.4) 1 (7.1) 0 (0.0) 1 (8.3)
  Median (Q1, Q3) 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (1, 1) 0 (0, 1)
Gestity
  Median (Q1, Q3) 4 (3, 6) 4 (3, 6) 3.5 (2, 5) 4 (3, 7) 5 (2.5, 6)
Parity
  Median (Q1, Q3) 4 (2, 5) 4 (2, 5) 3.5 (2, 5) 4 (2, 7) 4 (2.5, 5)
Profession
  Employed/professional 319 (46.9) 307 (47.4) 7 (50.0) 1 (14.3) 4 (33.3)
  Unemployed/housewife 361 (53.1) 340 (52.6) 7 (50.0) 6 (85.7) 8 (66.7)
Menarche
  Median (Q1, Q3) 14 (13, 15) 14 (13, 15) 15 (13, 15) 16 (14, 16) 14.5 (13, 16)
Age of marriage (n=654)
  Median (Q1, Q3) 19.5 (17, 24) 19 (17, 24) 21 (20, 25) 20 (18, 25) 20.5 (18, 24)
Age at first pregnancy (n=660)
  Median (Q1, Q3) 19 (17, 23) 19 (17, 23) 20 (18, 22) 20 (18, 25) 20 (18.5, 21.5)
Contraceptive use (>5 years)
  Yes 17 (2.5) 15 (2.3) 0 (0.0) 0 (0.0) 2 (16.7)
Alcohol consumption
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Result of visual inspection with 5% acetic acid
  Positive 38 (5.6) 11 (1.7) 11 (78.6) 7 (100.0) 9 (75.0)
Colposcopy result
  Positive 51 (7.5) 17 (2.6) 14 (100.0) 7 (100.0) 12 (100.0)
OncoE6 results (n=679)
  Positive 21 (3.1) 11 (1.7) 2 (15.4) 1 (14.3) 7 (58.3)
Cytology results (n=670)
  Normal 543 (81.0) 538 (84.5) 2 (14.3) 0 (0.0) 3 (25.0)
  ASCUS 14 (2.1) 12 (1.9) 1 (7.1) 0 (0.0) 1 (8.3)
  AGC 3 (0.4) 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
  LSIL 55 (8.2) 40 (6.3) 11 (78.6) 2 (28.6) 2 (16.7)
  HSIL 25 (3.7) 17 (2.7) 0 (0.0) 3 (42.9) 5 (41.7)
  ASC-H 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
  ICC 4 (0.6) 2 (0.3) 0 (0.0) 2 (28.6) 0 (0.0)
  Invalid 25 (3.7) 24 (3.8) 0 (0.0) 0 (0.0) 1 (8.3)
HPV result (n=670)
  Positive 256 (38.2) 224 (35.2) 13 (92.9) 7 (100.0) 12 (100.0)
*Excluding women with unsatisfactory colposcopy (n=27), women who refused/failed to be biopsied (n=5) and a woman with invalid histology 
result (n=1).
AGC, atypical glandular cell; ASC-H, atypical squamous cells cannot exclude high-grade lesion; ASCUS, atypical squamous cell of 
undetermined significance; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial 
lesion; ICC, invasive cervical cancer; LSIL, low-grade squamous intraepithelial lesion; Q1, 25th percentile; Q3, 75th percentile.
Table 1 Continued
the participants. A total of 713 women participated in 
the study, of whom 33 participants were excluded from 
the analyses (27 had unsatisfactory colposcopy, 5 had 
abnormal colposcopy and refused/failed to come for 
biopsy, and 1 woman had invalid histopathology result), 
resulting in 680 women being included in the final anal-
ysis. The median age of our participants was 44 years (IQR: 
37–52). Majority of the participants (316 women, 53.1%) 
went to primary school. Of the women, 286 (42.1%) were 
married or cohabiting, 247 (36.3%) were widowed and 
122 (17.9%) were divorced.
The median age at first intercourse was 18 years old 
(IQR: 16–20); the median number of lifetime sexual part-
ners was 3 (IQR: 2–4), and the median number of sexual 
partners in the last 6 months was 1 (IQR: 0–1). Majority 
of the participants (361, 53.1%) were employed or had a 
professional activity.
Prevalence of cervical cancer lesions and screening test 
results
Colposcopy was performed in all 713 participants and 
displayed abnormal results in 56 women. Biopsies for 
histopathology diagnosis were taken from 51 patients. 
Hence, colposcopy results served as a final diagnosis in 630 
women, while histopathology results served as a final diag-
nosis in 50 women. Among the 680 participants included 
in the analysis, 14 women (2.1%) had CIN1 lesions, 7 
(1%) had CIN2 lesions and 12 (1.8%) had CIN3/ICC 
lesions. With VIA, 38 women (5.6%) had a positive result. 
With the OncoE6 test, 21 women (3.1%) had a positive 
result. Positivity rates were 15.2% and 38.2% for cytology 
and HPV-DNA test (Riatol qPCR), respectively.
Clinical performance of the tests used at different thresholds
The clinical performances of different screening tests are 
presented in table 2. At CIN2+ threshold, OncoE6 had 
sensitivity and specificity of 42.1% (95% CI 19.9 to 64.3) 
and 98% (95% CI 97 to 99.1), respectively, with a good 
PPV. VIA displayed both high sensitivity and high speci-
ficity, with the highest PPV. The HPV-DNA test displayed 
the highest sensitivity, with the lowest specificity and PPV.
In this report, we focus on the performance of the 
OncoE6 Cervical Test compared with cytology; other 
comparisons will be presented in further reports. The 
OncoE6 test had a lower performance in diagnosing 
CIN2+ lesions, compared with cytology at ASCUS+ and 
LSIL+ cut-offs (AUC=0.68 vs 0.85, p=0.03 and AUC=0.68 
vs 0.83, p=0.04, respectively (Area Under the Curve, 
AUC)) (see online supplementary figure 1). However, 
the performance of OncoE6 test was as good as cytology 
at HSIL+ cut-off (AUC=0.68 vs 0.76, p=0.30).
At CIN3+ threshold, OncoE6 had both the highest 
specificity and PPV. VIA also had high specificity. The 
sensitivity and specificity for cytology were 45.5% (95% CI 
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16 to 74.9) and 96.1% (95% CI 94.5 to 97.6), respectively, 
and had the lowest PPV.
The performance of the OncoE6 test was not signifi-
cantly different from that of cytology at ASCUS+, LSIL+ 
and HSIL+ cut-offs in diagnosing CIN3+ lesions (p1=0.76, 
p2=0.95 and p3=0.50, respectively).
Clinical performance of the algorithm hPV+, followed by 
Oncoe6 or VIA test
A screening algorithm consisting of a first screening test 
using the Riatol qPCR HPV test and a second test (OncoE6 
test or VIA) only for women who tested HPV-positive on 
the first test, to identify CIN2+ or CIN3+ lesions, suggests 
that the clinical performance of OncoE6 or VIA did not 
improve (table 3).
dIsCussIOn
Our report shows a proportion of cervical intraepithelial 
lesions of 4.9% in this never-screened, HIV-positive Burun-
dian women population. To our knowledge, this study is 
the first report from Burundi attempting to provide accu-
rate data on the prevalence of cervical precancer lesions 
confirmed by colposcopy and/or histopathology among 
HIV-positive women. All study participants received 
standardised colposcopy evaluation, and biopsies for 
histopathology confirmation were taken when clinically 
recommended.24–26
Clinical implications of the results
In this study, the performance of OncoE6 in predicting 
CIN2+ and CIN3+ diagnoses was evaluated. The sensi-
tivity of OncoE6 in detecting CIN lesions increased 
with increasing disease severity—42.1% and 58.3% 
for CIN2+ and CIN3+, respectively—and corroborates 
previous findings.7 17 A major drawback of this test’s low 
sensitivity is its inability to detect a high proportion of 
cervical precancerous lesions that, if treated, would have 
resulted in reduced incidence and mortality related to 
ICC. Adhering to the WHO recommendations13 to treat 
HIV-positive women with CIN2+ lesions, the performance 
of the OncoE6 test was significantly lower compared with 
cytology at ASCUS+ cut-off.
This low sensitivity may be due to the fact that a 
substantial proportion of cervical lesions among these 
HIV-infected women were caused by HR-HPV types other 
than HPV 16/18 included in the current version of the 
test. In fact, only 12 women out of 19 with histologically 
confirmed CIN2+ lesions (63.2%) were HPV 16-positive 
or HPV 18-positive (online supplementary table 1). This 
implies that at least 37% of all CIN2+ were associated with 
HR-HPV types other than the HPV 16 and 18 types.
Another hypothesis of the low sensitivity of the OncoE6 
Cervical Test may be the possibility of HPV-related lesions 
with a lower progressive potential being missed. This may 
be due to the ability of the E6 oncoprotein to biologically 
differentiate between HPV-related lesions with a high 
progressive potential (thus, testing OncoE6-positive) and 
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lesions with a lower progressive potential (resulting in 
OncoE6-negative), as has been reported by Valdez et al.18 
Nevertheless, our cross-sectional study design precludes 
us from exploring this hypothesis. An alternative expla-
nation of the low sensitivity of the OncoE6 test could be 
the potential mutations in the HPV 16 and 18 E6 DNA 
sequence, which alter the E6 oncoprotein binding to the 
anti-E6 specific monoclonal antibodies applied in the 
OncoE6 test, as documented by Krings et al.27 This could 
explain why the Riatol HPV test was in some samples 
positive for HPV 16 and 18, and the OncoE6 test being 
negative for the same samples. However, this hypothesis 
cannot be verified with our data.
Among the 12 women with 16/18-related CIN2+ 
lesions, 8 (66.7%) were OncoE6-positive. Our analyses 
show there were 17 cases of CIN2+ lesions related to 
HR-HPV types included in the nine-avalent vaccine (ie, 
16/18/31/33/45/52/58) were 17 cases. An improved 
OncoE6 test, including all these HR-HPV strains, with the 
same detection rate as the currently available test would 
have detected at least 12 cases. As a corollary, an improved 
OncoE6 test would have a sensitivity of 63.2% (12 of 19) 
in identifying CIN2+ lesions, which is higher than that of 
the current OncoE6 test.
On the other hand, we noted that the OncoE6 test 
had the highest specificity and PPV, compared with the 
HPV-DNA and cytology at all cut-offs in detecting CIN2+ 
and CIN3+ lesions. This finding was similar to other 
OncoE6 validation data published in other settings7 17 
and suggests that OncoE6 may be more useful than HPV 
and cytology in detecting CIN2+ lesions. Given this attri-
bute, Zhao et al17 have suggested that OncoE6 could be 
useful for screening high-risk populations, including 
HIV-infected women among others. However, our anal-
yses highlight the limitations of the test when used as a 
primary screening test for cervical precancer lesions in 
this high-risk population of HIV-infected women. More-
over, the use of OncoE6 as a triage test for HPV-positive 
women did not result in an improved sensitivity of the 
test.
At CIN3+ threshold, nearly 60% of clinically important 
disease (CIN3+) could be identified with OncoE6. The 
study by Qiao et al19 also found similar values of spec-
ificity and sensitivity of OncoE6 in identifying CIN3+ 
cervical lesions. At different cytology cut-offs, OncoE6 
was performing at least as well as cytology. Among the 
12 CIN3+ cases, 75% were HPV 16/18-related, of which 
the OncoE6 test was positive in 66.7% (6 of 9), as it was 
also for CIN2+ diagnosis. Of all CIN3+ cases, 91.7% (11 
of 12) were related to HR-HPV types included in the 
nine-valent vaccine, which implies that 8 CIN3+ lesions 
would have been detected, resulting in a sensitivity of 
66.7%.
This implies that given the barriers to implementing 
a cytology-based screening programme, an improved 
OncoE6 Cervical Test with more HPV strains may be an 
option to be considered by test developers due to it being 
amenable to a see-and-treat approach.
The current version of OncoE6 test includes 16/18 HPV 
types and has a lower clinical performance, compared 
with cytology at ASCUS+ cut-off, for CIN2+ diagnoses.
In our analysis, VIA proved to have both high sensitivity 
and high specificity for CIN2+ diagnoses, along with the 
highest PPV. This corroborates the WHO recommen-
dations8 13 to use VIA in ‘a screen and treat’ approach 
in resource-constrained settings, for cervical cancer 
screening, even just once in a woman’s lifetime.
In the context of the absence of a screening strategy, as 
it is currently the case for Burundi, any investment to be 
made for cervical cancer screening should first consider 
visual inspection-based strategy as the most feasible. 
The OncoE6 test might be justifiable as a triage test for 
screened positive women given its highest specificity and 
ease of use. However, cost-effectiveness analyses are also 
needed to further elucidate the suitability of this strategy.
strengths and limitations
Our study was conducted in a pragmatic setting, where 
OncoE6 Cervical Test proved to be a point-of-care test. 
Another strength is that all women underwent colpo-
scopic evaluation, although colposcopy is not univocally 
considered as gold standard and has limitations in iden-
tifying all CIN2+ lesions.28 However, we acknowledge an 
important limitation of this study. Women who had no 
visible lesions at colposcopy could not be biopsied, and 
therefore we may have overestimated the clinical estimated 
parameters of the test evaluated, as has been previously 
documented.19 28 However, some authors have also raised 
concerns related to biopsies on normal-appearing cervix 
to ascertain the status of the cervix.29 While balancing 
ethical concerns and conforming to the best clinical prac-
tices, our approach represented a comprehensive effort 
for improving the precision of our parameter estimates, 
and thus our ‘composite colposcopic-histological diag-
nosis’ was a reliable proxy as gold standard. The lower 
performance of the test in identifying CIN2+ lesions 
makes it inappropriate for primary screening of cervical 
precancerous lesions.
COnClusIOns
This study focused on the field use of the currently avail-
able OncoE6 Cervical Test, and displayed low sensitivity, 
high specificity and high PPV for CIN2+ diagnoses. 
Given its low sensitivity and poor performance in identi-
fying CIN2+ lesions, we do not recommend the OncoE6 
Cervical Test for primary screening. We highlighted the 
need for an OncoE6TM test to incorporate a wide range of 
HR-HPV strains, which would result in a good test perfor-
mance for primary cervical cancer screening with less 
stringent equipment and personnel requirements. In the 
meantime, and in the absence of other alternatives for 
cervical cancer screening, low-income countries should 
first consider implementing a visual inspection-based 
strategy as recommended by WHO. Taking into account 
the Burundian context, appropriate screening strategies 
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for Burundi and other LMICs will undoubtedly differ 
from strategies appropriate for a high-income country.
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